Meeting
2024 ASCO Annual Meeting
H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).
Authors
Stephen R. D. Johnston
Royal Marsden NHS Foundation Trust, London, United Kingdom
Stephen R. D. Johnston , Timothy J. Pluard , Judy S. Wang , Erika P. Hamilton , Tingting Song , Yuanxin Rong , Kohei Yamaguchi , Dejan Juric
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT04288089
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 1051)
DOI
10.1200/JCO.2024.42.16_suppl.1051
Abstract #
1051
Poster Bd #
29
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC).
First Author: Akshara Singareeka Raghavendra
Poster
2021 ASCO Annual Meeting
Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
First Author: Judith Michels
Poster
2020 ASCO Virtual Scientific Program
Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).
First Author: Seth Andrew Wander
Poster
2019 Genitourinary Cancers Symposium
A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.
First Author: Albert Font Pous